StockData

NanoViricides, Inc. (NNVC) stock

NNVCNYSEPharmaceutical PreparationsFiscal year ends June 30
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 5/30
$1.17−0.02 (-1.68%)

Close on Nov 19, 2026Market cap $29.86MP/E –Yield –

NanoViricides free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

NanoViricides's free cash flow for the twelve months ending Jun 30, 2026 was -$7.78M. For fiscal 2026 it was -$7.78M. The highest annual figure on record is -$2.61M in fiscal 2010.

Annual free cash flow

PeriodPeriod endValueChange
FY2026Jun 30, 2026-$7.78M–
FY2025Jun 30, 2025-$8.54M–
FY2024Jun 30, 2024-$6.47M–
FY2023Jun 30, 2023-$5.82M–
FY2022Jun 30, 2022-$6.22M–
FY2021Jun 30, 2021-$8.45M–
FY2020Jun 30, 2020-$6.67M–
FY2019Jun 30, 2019-$6.88M–
FY2018Jun 30, 2018-$8.02M–
FY2017Jun 30, 2017-$8.06M–
FY2016Jun 30, 2016-$7.31M–
FY2015Jun 30, 2015-$12.97M–
FY2014Jun 30, 2014-$11.56M–
FY2013Jun 30, 2013-$5.86M–
FY2012Jun 30, 2012-$4.24M–
FY2011Jun 30, 2011-$4.66M–
FY2010Jun 30, 2010-$2.61M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q4 FY2026CQ2 2026Jun 30, 2026-$2.12M–
Q3 FY2026CQ1 2026Mar 31, 2026-$1.93M–
Q2 FY2026CQ4 2025Dec 31, 2025-$2.05M–
Q1 FY2026CQ3 2025Sep 30, 2025-$1.68M–
Q4 FY2025CQ2 2025Jun 30, 2025-$1.71M–
Q3 FY2025CQ1 2025Mar 31, 2025-$1.99M–
Q2 FY2025CQ4 2024Dec 31, 2024-$2.19M–
Q1 FY2025CQ3 2024Sep 30, 2024-$2.64M–
Q4 FY2024CQ2 2024Jun 30, 2024-$1.58M–
Q3 FY2024CQ1 2024Mar 31, 2024-$1.99M–
Q2 FY2024CQ4 2023Dec 31, 2023-$1.72M–
Q1 FY2024CQ3 2023Sep 30, 2023-$1.18M–
Q4 FY2023CQ2 2023Jun 30, 2023-$1.50M–
Q3 FY2023CQ1 2023Mar 31, 2023-$1.80M–
Q2 FY2023CQ4 2022Dec 31, 2022-$1.45M–
Q1 FY2023CQ3 2022Sep 30, 2022-$1.08M–
Q4 FY2022CQ2 2022Jun 30, 2022-$1.47M–
Q3 FY2022CQ1 2022Mar 31, 2022-$1.69M–
Q2 FY2022CQ4 2021Dec 31, 2021-$2.30M–
Q1 FY2022CQ3 2021Sep 30, 2021-$748.54K–
Q4 FY2021CQ2 2021Jun 30, 2021-$2.31M–
Q3 FY2021CQ1 2021Mar 31, 2021-$1.55M–
Q2 FY2021CQ4 2020Dec 31, 2020-$2.32M–
Q1 FY2021CQ3 2020Sep 30, 2020-$2.27M–
Q4 FY2020CQ2 2020Jun 30, 2020-$1.71M–
Q3 FY2020CQ1 2020Mar 31, 2020-$2.40M–
Q2 FY2020CQ4 2019Dec 31, 2019-$1.13M–
Q1 FY2020CQ3 2019Sep 30, 2019-$1.44M–
Q4 FY2019CQ2 2019Jun 30, 2019-$1.68M–
Q3 FY2019CQ1 2019Mar 31, 2019-$2.02M–
Q2 FY2019CQ4 2018Dec 31, 2018-$2.18M–
Q1 FY2019CQ3 2018Sep 30, 2018-$999.41K–
Q4 FY2018CQ2 2018Jun 30, 2018-$3.54M–
Q3 FY2018CQ1 2018Mar 31, 2018-$1.43M–
Q2 FY2018CQ4 2017Dec 31, 2017-$1.47M–
Q1 FY2018CQ3 2017Sep 30, 2017-$1.59M–
Q4 FY2017CQ2 2017Jun 30, 2017-$1.06M–
Q3 FY2017CQ1 2017Mar 31, 2017-$2.15M–
Q2 FY2017CQ4 2016Dec 31, 2016-$2.61M–
Q1 FY2017CQ3 2016Sep 30, 2016-$2.25M–

More NanoViricides figures

See a number that looks wrong?